atl1103 anti cancer medications, page-41

Whoever did that may think that the Australia do not do the same kick-backs for Orphan drugs as the US.

Australia follow the US processes to be able to sell in to the biggest market in the world. Australia offers the same benefits for orphan drug development as the US, with the condition of a passing a 'cost effective analysis' set out by Pharmaceutical Benefits Advisory Committee Australia.

We know the finished product (ALT1103) will undercut Somavert by 50% so I can not see ANP failing the CEA test.

DYOR and look closer guys we are on a good thing here!